FDA To Discuss Regulation of OTC Products
Might Some Prescription Drugs Become More Accessible?
ROCKVILLE, MD- The Food and Drug Administration (FDA) will convene a public meeting on June 28 and 29, 2000 in Gaithersburg, MD, to discuss their approach to regulating over-the-counter (OTC) drug products. Issues of interest include:
1. Criteria to be considered for decisions on OTC availability.
2. Classes of drug products that should or should not be made available OTC.
3. Consumer ability to understand OTC product benefits and risks.
4. Whether the current structure for marketing OTC products is adequate.
5. How rational treatment decisions will be affect by coexisting prescription and OTC therapies.
6. The FDA's role in changing prescription drugs to OTC status.
The FDA is soliciting information and opinions from interested parties. Those who wish to participate in the hearing must file a written notice of participation with the Dockets Management Branch by June 2, 2000. Submissions can be mailed to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852; or emailed to FDADockets@oc.fda.gov.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
